Compounds > 2-(aminomethyl)phenol
Page last updated: 2024-12-06

2-(aminomethyl)phenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID70267
CHEMBL ID155572
CHEMBL ID3114402
SCHEMBL ID110156
MeSH IDM0101209

Synonyms (46)

Synonym
nsc-127870
nsc127870
932-30-9
CHEMBL155572
2-(aminomethyl)phenol
2-aminomethyl-phenol
FT-0652646
AKOS000126449
A844480
2-(aminomethyl)-phenol
EN300-64465
(aminomethyl)phenol
einecs 256-534-1
50312-64-6
2-hydroxybenzylamine
unii-696r5n4nrm
einecs 213-249-7
nsc 127870
696r5n4nrm ,
PS-3546
CHEMBL3114402 ,
bdbm50446752
SCHEMBL110156
AM83184
MB01565
2-aminomethylphenol
o-hydroxybenzylamine
KPRZOPQOBJRYSW-UHFFFAOYSA-N
o-hydroxy-benzylamine
mfcd00870498
SY018673
STR07386
AC-30803
phenol,(aminomethyl)-
2-(aminomethyl)phenol, aldrichcpr
CS-D1655
2-hydroxybenzylamine, (2-hydroxyphenyl)methylamine
o-aminomethylphenol
J-506197
2-hoba
2-hydroxylbenzylamine
DB14855
DTXSID70902921
noname_3497
2-hydroxybenzyl amine
HY-34350

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Reported adverse events were mild and considered unlikely to be related to 2-HOBA."( First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.
Abumrad, NN; Akers, WS; Amarnath, V; Boutaud, O; Currey, PM; Daniels, JS; Fuller, JC; Morrison, RD; Oates, JA; Pitchford, LM; Rathmacher, JA; Roberts, LJ, 2019)		0.51
"2-HOBA acetate was safe and well-tolerated at doses up to 825 mg in healthy human volunteers, positioning it as a good candidate for continued development as a nutritional supplement."( First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.
Abumrad, NN; Akers, WS; Amarnath, V; Boutaud, O; Currey, PM; Daniels, JS; Fuller, JC; Morrison, RD; Oates, JA; Pitchford, LM; Rathmacher, JA; Roberts, LJ, 2019)		0.51
"Repeated oral administration of 2-HOBA was found to be safe and well-tolerated up to 750 mg TID for 15 days."( Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial.
Abumrad, NN; Akers, WS; Amarnath, V; Boutaud, O; Chen, SC; Driver, PM; Fuller, JC; Milne, GL; Oates, JA; Pitchford, LM; Rathmacher, JA; Roberts, LJ; Shoemaker, MB; Ye, F, 2020)		0.56
"Repeated oral administration of 2-HOBA was found to be safe and well-tolerated."( Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial.
Abumrad, NN; Akers, WS; Amarnath, V; Boutaud, O; Chen, SC; Driver, PM; Fuller, JC; Milne, GL; Oates, JA; Pitchford, LM; Rathmacher, JA; Roberts, LJ; Shoemaker, MB; Ye, F, 2020)		0.56

Dosage Studied

ExcerptRelevanceReference
" In the acute dosing study, 2000 mg/kg BW 2-HOBA resulted in mortality in one of the six tested female rats, indicating a median lethal dose of 2500 mg/kg BW."( Acute and 28-day repeated dose toxicity evaluations of 2-hydroxybenzylamine acetate in mice and rats.
Abumrad, NN; Fuller, JC; Pitchford, LM; Rathmacher, JA; Smith, JD, 2018)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID62355Saluretic property in average of two anesthetized dogs after 5 mg/kg iv administration1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
2-(Aminomethyl)phenols, a new class of saluretic agents. 5. Fused-ring analogues.
AID190442Saluretic property after 50 mg/kg oral administration in rats1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
2-(Aminomethyl)phenols, a new class of saluretic agents. 5. Fused-ring analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.79)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (31.58)24.3611
2020's10 (52.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.51 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.67 (0.95)

This Compound (21.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (15.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyridoxine
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).		2.2510hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		1.9610chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		1.9610benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.6620dialdehydebiomarker
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.2110acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		5.2531benzenes;
phenyl acetates
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.2510aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
gastrins
Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.		2.610
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Stomach
[description not available]		03.6150
Infections, Helicobacter
[description not available]		03.6150
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		03.6150
Stomach Neoplasms
Tumors or cancer of the STOMACH.		03.6150
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		03.6150
Innate Inflammatory Response
[description not available]		03.8330
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		03.8330
Colorectal Cancer
[description not available]		02.610
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.610
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9430
Elevated Cholesterol
[description not available]		02.2510
Apolipoprotein B-100, Familial Defective
[description not available]		02.6620
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		02.2510
Hyperlipoproteinemia Type II
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).		02.6620
Atherogenesis
[description not available]		02.2510
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.2510
Colitis-Associated Cancer
[description not available]		02.3110
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.3110
Metaplasia
A condition in which there is a change of one adult cell type to another similar adult cell type.		02.3110
Condition, Preneoplastic
[description not available]		02.3110
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.3110
Auricular Fibrillation
[description not available]		04.6211
Local Neoplasm Recurrence
[description not available]		04.6211
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		04.6211
Esophageal Reflux
[description not available]		02.2110
Gastroesophageal Reflux
Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.		02.2110
Left Ventricular Hypertrophy
[description not available]		02.2110
Left Ventricular Dysfunction
[description not available]		02.2110
Cardiac Remodeling, Ventricular
[description not available]		02.2110
Cardiac Hypertrophy
Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.		02.2110
Cardiac Failure
[description not available]		02.2110
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		02.2110
Cardiomegaly
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.		02.2110
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.2110
Pneumonia
Infection of the lung often accompanied by inflammation.		02.2110
Hypertrophy, Left Ventricular
Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.		02.2110
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		02.2110
Pulmonary Arterial Remodeling
[description not available]		03.0310
Blood Pressure, High
[description not available]		03.0310
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		03.0310
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		03.0310